fda semaglutide compounding enforcement november 2025 issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Compounded weight loss drugs get

The skyrocketing cost of weight-loss drugs has state Medicaid programs looking for a solution Read full article: The skyrocketing cost of weight-loss drugs has state Medicaid programs looking for a solution Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid or state employee insurance programs are scrambling to lessen the budgetary squeeze from fast-rising costs

[Office of disease prevention and health promotion USDoHaHS

Nausea is one of the most common side effects during the first weeks of semaglutide therapy, affecting roughly 25-30% of patients in clinical trials

Its distinctive multi-receptor activity impacts fat loss, muscle preservation, metabolism, and hormones